Evidence map›Paper›PMID 31861091›Full record

ArticleCancers2019

Pathways, Processes, and Candidate Drugs Associated with a

Laura M Kettyle, Charles-Étienne Lebert-Ghali, Ivan V Grishagin, Glenda J Dickson, Paul G O'Reilly, David A Simpson, Janet J Bijl, Ken I Mills, Guy Sauvageau, Alexander Thompson

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Laura M KettyleCentre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast BT9 7AE, UK.
Charles-Étienne Lebert-GhaliMaisonneuve-Rosemont Hospital Research Center, Montréal, QC H1T 2M4, Canada.
Ivan V GrishaginCentre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast BT9 7AE, UK.
Glenda J DicksonKing's College London, Division of Cancer Studies, London WC2R 2LS, UK.ORCID 0000-0002-5606-2708
Paul G O'ReillyCentre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast BT9 7AE, UK.
David A SimpsonCentre for Experimental Medicine, Queen's University Belfast, Belfast BT9 7BL, UK.
Janet J BijlMaisonneuve-Rosemont Hospital Research Center, Montréal, QC H1T 2M4, Canada.ORCID 0000-0003-1436-3075
Ken I MillsCentre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast BT9 7AE, UK.
Guy SauvageauDepartment of Medicine, Université de Montréal, Montréal, QC H3G 2M1, Canada.
Alexander ThompsonCentre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast BT9 7AE, UK.
Queen's University Belfast · GBHôpital Maisonneuve-Rosemont · CAKing's College London · GB

Funding

Bloodwise 09035Canadian Cancer Society 20399Leukaemia and Lymphoma NI R2054CNRLeukaemia and Lymphoma NI R2055CNR
6 · The paper itself

Abstract

High expression of the

Indexed as

candidate drugsconditional deletiongene signatureHOXA clusterleukemia maintenanceMLL-rearrangementpathways

Identifiers

PMID31861091
PMCPMC6966468
OpenAlexW2995409991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.